TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...
In a media briefing streamed live on Canada's Global News, Bonnie Henry, MD, BC's health officer, shared the latest investigation ... (Schnirring, 11/12) Novavax yesterday announced that the US Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback